Curcumin-Based Treatment for Macular Edema from Uncommon Etiologies: Efficacy and Safety Assessment

다국어 초록 (Multilingual Abstract)

The aim of this study was to investigate the efficacy and safety of curcumin formulation with a polyvinylpyrrolidone-hydrophilic carrier (CHC*; Diabec®—AlfaIntes, Italy) for the treatment of macular edema (ME) from uncommon etiologies. We conducted retrospective interventional case series, reviewing the medical records of patients referred to the Eye Center, Humanitas Hospital, Bergamo due to persistent ME related to uncommon causes and treated by oral administration of CHC. The main outcomes assessed were best-corrected visual acuity (BCVA), central macular thickness (CMT), and the presence of intraretinal and/or subretinal fluid (SRF). Only patients with a minimum follow-up (f/u) of 6 months were included. The occurrence of any adverse effect was registered. Thirty-one eyes of 30 patients were included, with a mean f/u of 8.32 ± 1.77 months. Of them, 9 patients (10 eyes) were affected by postoperative ME and 21 by chronic central serous chorioretinopathy. Median BCVA significantly improved after treatment, changing from 0.3 [0.16–0.5] to 0.1 [0–0.3] logarithm of the minimum angle of resolution (P < .001). Also CMT was significantly improved, as it decreased from 400 [364–438] μm before treatment to 280 [242–307] μm at the last f/u visit (P < .001). The complete absorption of intraretinal/SRF was detected in 23 of 31 eyes (74%) at the final f/u. No adverse effects were registered. In conclusion, treatment with CHC was effective and safe for eyes affected by ME of various uncommon etiologies, resulting in significant improvement of both functional and anatomical outcomes, with the complete resolution of the edema in the majority of cases (74%).

참고문헌 (Reference)

1 Wolfensberger TJ, "Treatment of cystoid macular edema with non-steroidal anti-inflammatory drugs and corticosteroids" 97 : 381-386, 1999

2 Peddada KV, "Therapeutic potential of curcumin in major retinal pathologies" 39 : 725-734, 2019

3 Kim JY, "Short-term efficacy of subthreshold micropulse yellow laser(577-nm)photocoagulation for chronic central serous chorioretinopathy" 253 : 2129-2135, 2015

4 Platania CBM, "Retinal protection and distribution of curcumin in vitro and in vivo" 9 : 670-, 2018

5 Sahdeo Prasad, "Recent Developments in Delivery, Bioavailability, Absorption and Metabolism of Curcumin: the Golden Pigment from Golden Spice" 대한암학회 46 (46): 2-18, 2014

6 Benitah NR, "Pseudophakic cystoid macular edema" 50 : 139-153, 2010

7 Mazzolani F, "Pilot study of oral administration of a curcuminphospholipid formulation for treatment of central serous chorioretinopathy" 6 : 801-806, 2012

8 Malchiodi-Albedi F, "PPAR-gamma, microglial cells, and ocular inflammation : New venues for potential therapeutic approaches" 2008 : 295784-, 2008

9 Mazzolani F, "Oral administration of a curcuminphospholipid delivery system for the treatment of central serous chorioretinopathy : A 12-month follow-up study" 7 : 939-945, 2013

10 Mazzolani F, "Oral administration of a curcumin-phospholipid formulation(Meriva)for treatment of chronic diabetic macular edema : A pilot study" 22 : 3617-3625, 2018

11 Daruich A, "Mechanisms of macular edema : Beyond the surface" 63 : 20-68, 2018

12 Jacob A, "Mechanism of the antiinflammatory effect of curcumin : PPAR-gamma activation" 2007 : 89369-, 2007

13 Koutsandrea C, "Intraocular triamcinolone acetonide for pseudophakic cystoid macular edema : Optical coherence tomography and multifocal electroretinography study" 27 : 159-164, 2007

14 Ren YX, "Effects of curcumin on epidermal growth factor in proliferative vitreoretinopathy" 47 : 2136-2146, 2018

15 Bellocq D, "Effectiveness and safety of dexamethasone implants for postsurgical macular oedema including Irvine-Gass syndrome : The EPISODIC-2 study" 101 : 333-341, 2017

16 Mrudula T, "Effect of curcumin on hyperglycemia-induced vascular endothelial growth factor expression in streptozotocin-induced diabetic rat retina" 361 : 528-532, 2007

17 Dutra Medeiros M, "Dexamethasone intravitreal implant for treatment of patients with recalcitrant macular edema resulting from IrvineGass syndrome" 54 : 3320-3324, 2013

18 Farajipuor H, "Curcumin: A new candidate for retinal disease therapy?" 120 : 6886-6893, 2019

19 Sandur SK, "Curcumin, demethoxycurcumin, bisdemethoxycurcumin, tetrahydrocurcumin and turmerones differentially regulate anti-inflammatory and antiproliferative responses through a ROS independent mechanism" 28 : 1765-1773, 2007

20 Gupta SK, "Curcumin prevents experimental diabetic retinopathy in rats through its hypoglycemic, antioxidant, and anti-inflammatory mechanisms" 27 : 123-130, 2011

21 Yang F, "Curcumin alleviates diabetic retinopathy in experimental diabetic rats" 60 : 43-54, 2018

22 Pescosolido N, "Curcumin : Therapeutical potential in ophthalmology" 80 : 249-254, 2014

23 Ja¨ger R, "Comparative absorption of curcumin formulations" 13 : 11-, 2014

24 Cuomo J, "Comparative absorption of a standardized curcuminoid mixture and its lecithin formulation" 74 : 664-669, 2011

25 Daruich A, "Central serous chorioretinopathy : Recent findings and new physiopathology hypothesis" 48 : 82-118, 2015

26 Liegl R, "Central serous chorioretinopathy" 232 : 65-76, 2014

27 Anand P, "Bioavailability of curcumin : Problems and promises" 4 : 807-818, 2007

28 Jayaprakasha GK, "Antioxidant activities of curcumin, demethoxycurcumin and bisdemethoxycurcumin" 98 : 720-724, 2006

29 Yu Y, "Anti-inflammatory effects of curcumin in microglial cells" 9 : 386-, 2018

30 Catier A, "Advantages of acetazolamide associated with anti-inflammatory medications in postoperative treatment of macular edema" 28 : 1027-1031, 2005

31 Stohs SJ, "A comparative pharmacokinetic assessment of a novel highly bioavailable curcumin formulation with 95% curcumin : A randomized, double-blind, crossover study" 37 : 51-59, 2018